Abstract
The effects of chronic administration of the selective 5-HT3 receptor antagonist ondansetron (GR38032F) on dopamine (DA) and 5-hydrotryptamine (5-HT) metabolism in the major ascending dopaminergic neurons and on striatal D2-receptor binding characteristics were investigated. The metabolism of 5-HT was also studied in a number of other brain areas. Chronic ondansetron (0.2 mg/kg/day and 1.0 mg/kg/day SC for 16 days) did not change DA or 5-HT metabolism in the nigrostriatal or mesolimbic dopaminergic areas, although the larger dose of ondansetron slightly and statistically significantly reduced basal concentrations of DA and 5-HT in the nucleus caudatus. D2-receptor binding characteristics were not affected in the caudateputamen. Ondansetron did not change 5-HT metabolism in the nucleus raphé dorsalis, amygdala, hippocampus or in habenula. It is concluded that chronic administration of ondansetron does not change DA or 5-HT metabolism in the major ascending dopaminergic neurons. This suggest that unlike chronic D2-receptor blockade, chronic blockade of central 5-HT3 receptors does not result in a similar reduction in the activity of nigrostriatal and mesolimbic dopaminergic neurons.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bradley PB, Engel G, Feniuk W, Fozard JR, Humprey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576
Bunney BS, Grace AA (1978) Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 25:1715–1728
Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB (1988) Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 94:397–412
Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881–894
Hagan RM, Butler A, Hill JM, Jordan CC, Ireland SJ, Tyers MB (1987) Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol 138:303–305
Hietala J, Syvälahti E, Röyttä M (1988) Comparison of neuroleptic binding characteristics in rat striatum and renal cortex. J Recept Res 6:753–771
Kelland MD, Freeman AS, Chiodo LA (1989) Chloral hydrate anesthesia alters the responsiveness of identified midbrain dopamine neurons to dopamine agonist administration. Synapse 3:30–37
Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330:746–748
Kilpatrick GJ, Jones BJ, Tyers MB (1989) Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 159:157–164
Koulu M, Saavedra JM, Niwa M, Linnoila M (1986) Increased catecholamine metabolism in locus coeruleus of young spontaneously hypertensive rats. Brain Res 369:361–364
Koulu M, Sjöholm B, Lappalainen J, Virtanen R (1989) Effects of acute GR38032F (odansetron), a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons. Eur J Pharmacol 169:321–324
Lappalainen J, Hietala J, Koulu M, Seppälä T, Sjöholm B, Syvälahti E (1990) Chronic treatment with SCH 23390 and haloperidol: effects on dopaminergic and serotonergic mechanisms in rat brain. J Pharmacol Exp Ther (in press)
Lindefors N, Sharp T, Ungerstedt U (1986) Effects of subchronic haloperidol and sulpiride on regional brain dopamine metabolism in the rat. Eur J Pharmacol 129:401–404
Matsumoto T, Uchimura H, Hirano M, Kim JS, Hideyasu Y, Nakahara M, Inoue K, Oomagari K (1983) Differential effects of acute and chronic administration of haloperidol on homovanillic acid levels in discrete dopaminergic areas of rat brain. Eur J Pharmacol 89:27–33
McPherson G (1985) Analysis of radioligand binding experiments: a collection of computer programs for IBM PC. J Pharmacol Methods 14:213–228
Mefford IN, Roth K, Agren H, Barchas JD (1988) Enhancement of dopamine metabolism in rat brain frontal cortex: a common effect of chronically administered antipsychotic drugs. Brain Res 475:380–384
Munson PJ, Rodbard D (1980) LIGAND: a versatile computerized approach for the characterization of ligand binding systems. Anal Biochem 107:220–239
Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is generally more applicable. Anal Biochem 83:346–356
Reynolds GP (1983) Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305:527–528
Scatton B, Garret C, Julou L (1975) Acute and subacute effects of neuroleptics on dopamine synthesis and release in the rat striatum. Naunyn Schmiedeberg's Arch Pharmacol 289:419–434
Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32:229–313
Sorensen SM, Humpreys TM, Palfreyman MG (1989) Effect of acute and chronic MDL73147EF, a 5-HT3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 163:115–118
Tricklebank MD (1989) Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. TIPS 10:127–129
Trimble MR, Rogers D (1987) Neurological disorder and schizopheria. In: Henn FA, DeLisi LE (eds) Handbook of schizophrenia, vol 2: Neurochemistry and neuropharmacology of schizophrenia. Elsevier, Amsterdam, pp 439–465
White WF, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054–1057
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koulu, M., Lappalainen, J., Hietala, J. et al. Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding. Psychopharmacology 101, 168–171 (1990). https://doi.org/10.1007/BF02244121
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244121